The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.
 
Howard A. Burris
No Relationships to Disclose
 
Herbert Hurwitz
Honoraria - Roche Pharma AG
Consulting or Advisory Role - Amgen; Genentech; Lilly; Roche Pharma AG; TRACON Pharma
Research Funding - Amgen; Bristol-Myers Squibb; Genentech; Lilly; Roche Pharma AG; TRACON Pharma
 
Edith A. Perez
No Relationships to Disclose
 
David Spigel
No Relationships to Disclose
 
Charles Swanton
Stock and Other Ownership Interests - Epic Sciences
Honoraria - Boehringer Ingelheim; GlaxoSmithKline; Novartis (I); Roche
Consulting or Advisory Role - Sarah Cannon Research Institute
Research Funding - Boehringer Ingelheim
 
John D. Hainsworth
Research Funding - Genentech (Inst)
 
Larry Leon
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Research Funding - Genentech
Travel, Accommodations, Expenses - Genentech
 
Mary Beattie
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Melissa Brammer
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Christopher Sweeney
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche